Oncaspar solution for injection
5 ml (1 vial) solution for injection contain pegaspargase equivalent to 3750 I.U. L-asparaginase.
Oncaspar® is indicated as a component of antineoplastic combination therapy for reinduction in acute lymphatic leukaemia in children and adults in patients with known hypersensitivity to "native" L-asparaginases.
Available pack sizes:
Vial N1